Dilemma: maintenance therapy enhances sclerogenic risk profile.
Jacobs
U
U
Department of General Internal Medicine, University Hospital, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.
Klein
B
B
Miersch
W D
WD
Molitor
D
D
Klehr
H U
HU
D000328:Adult; D000367:Age Factors; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000453:epidemiology*; D001379:Azathioprine / Q000009:adverse effects; D002784:Cholesterol / Q000097:blood*; D003348:Cortisone / Q000009:adverse effects; D016572:Cyclosporine / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000453:epidemiology; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology*; D008074:Lipoproteins / Q000097:blood; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D012307:Risk Factors; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*; D015430:Weight Gain
D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents; D008074:Lipoproteins; D014280:Triglycerides; D016572:Cyclosporine; D002784:Cholesterol; D001379:Azathioprine; D003348:Cortisone